Arbutus Biopharma Corporation ABUS

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
54/100
Moderate

Ranked against 712 peers in Biotechnology

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in … Full ABUS analysis →

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.80), demonstrating competitive advantages.
  • Operating Expense Control OpEx growth is controlled (score 0.62), demonstrating operating leverage.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.23), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
48
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ABUS ranks in Biotechnology

Arbutus Biopharma Corporation ranks #193 of 713 scored companies in Biotechnology by moat score — the top 27%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
189 Liquidia Corporation LQDA 54/100 Moderate
190 ProQR Therapeutics N.V. PRQR 54/100 Moderate
191 ZyVersa Therapeutics, Inc. ZVSA 54/100 Moderate
192 Beam Therapeutics Inc. BEAM 54/100 Moderate
193 Arbutus Biopharma Corporation ABUS 54/100 Moderate
194 Immatics N.V. IMTX 54/100 Moderate
195 Cellectis S.A. CLLS 54/100 Moderate
196 HOOKIPA Pharma Inc. HOOK 53/100 Moderate
197 Maravai LifeSciences Holdings, MRVI 53/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How ABUS scores on the Corporate Default defenses

Pricing Power

Score 48 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 62 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 54 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 46 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 50 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 64 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ABUS's moat

What is Arbutus Biopharma Corporation's moat score?

Arbutus Biopharma Corporation (ABUS) scores 54 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #193 of 713 scored companies in Biotechnology, the top 27%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (64/100) and its weakest is Capital Efficiency (46/100).

How does Arbutus Biopharma Corporation compare with other Biotechnology companies?

Arbutus Biopharma Corporation ranks #193 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Beam Therapeutics Inc. (BEAM) at 54 just above it and Immatics N.V. (IMTX) at 54 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Arbutus Biopharma Corporation scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Arbutus Biopharma Corporation?

The Corporate Default template measures 6 defenses, and ABUS scores: Pricing Power (48), Cost Advantage (62), Customer Stickiness (54), Capital Efficiency (46), Resilience (50), Scale & Market Position (64). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000